The global human milk oligosaccharides (HMO) market size is expected to reach USD 1303.59 million by 2032, according to a new study by Polaris Market Research. The report “Human Milk Oligosaccharides (HMO) Market Share, Size, Trends, Industry Analysis Report, By Type (2’FL, 3’FL, 3’SL, 6’SL); By Application; By Distribution Channel; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
Human Milk Oligosaccharides (HMOs) are complex carbohydrates or sugars naturally found in human breast milk. HMOs are unique to human milk and are not present in significant amounts in other mammalian milk, including cow's milk.
HMOs serve as a source of infant nutrition, although the baby does not directly digest them. Instead, they act as prebiotics, which means they serve as food for beneficial bacteria in the infant's gut. The gut microbiota is crucial in immune system development, digestion, and overall health. HMOs selectively promote the growth of specific beneficial bacteria, such as Bifidobacteria, while inhibiting the growth of harmful pathogens.
Human Milk Oligosaccharides (HMOs) are essential constituents of human breast milk and are available in various concentrations and compositions. The unique nature of HMOs requires specific regulatory approvals for their use. In the United States, oligosaccharides are authorized to be incorporated into food products rather than categorized as dietary supplements and are subject to the Generally Recognized as Safe (GRAS) regulations.
For instance, the GRAS-approved HMO product line is CARE4U, developed by DuPont, which is utilized in infant formula and toddler foods. This approval ensures its safety for consumption. Furthermore, the growing demand for HMOs has led to a novel food safety assessment to seek support from the European Commission for their usage.
Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below: https://www.polarismarketresearch.com/industry-analysis/human-milk-oligosaccharides-hmo-market/request-for-sample
The global adoption of Human Milk Oligosaccharides (HMOs) has increased. According to a World Economic Forum article published in January 2022, the number of births in Japan decreased by 2.8% in 2020 compared to the previous year, reaching its lowest point since 1899.
The increasing demand for HMOs can be attributed to lifestyle improvements and a growing focus on health and wellness. HMOs are utilized in functional food and beverage products and food supplements to address disorders and mitigate high-risk health conditions. This factor has significantly contributed to the growth of the global HMO industry. However, the high costs associated with HMO products are expected to pose a major challenge to market growth during the forecast period.
The COVID-19 pandemic has had a significant impact on the HMO industry. During the initial phase of the pandemic, there was a surge in demand for HMOs as consumers engaged in panic buying for at-home consumption. It resulted in increased sales of HMOs, considered immune-boosting products.
Human Milk Oligosaccharides (HMO) Market Report Highlights
Polaris Market Research has segmented the human milk oligosaccharides (HMO) market report based on type, application, distribution channel, and region:
Human Milk Oligosaccharides (HMO), Type Outlook (Revenue - USD Million, 2019 - 2032)
Human Milk Oligosaccharides (HMO), Application Outlook (Revenue - USD Million, 2019 - 2032)
Human Milk Oligosaccharides (HMO), Distribution Channel Outlook (Revenue - USD Million, 2019 - 2032)
Fogless Mirror, Regional Outlook (Revenue - USD Million, 2019 - 2032)
Report Attributes |
Details |
Market size value in 2024 |
USD 255.86 million |
Revenue forecast in 2032 |
USD 1303.59 million |
CAGR |
22.6% from 2024 – 2032 |
Base year |
2023 |
Historical data |
2019 – 2022 |
Forecast period |
2024 – 2032 |
Quantitative units |
Revenue in USD million and CAGR from 2024 to 2032 |
Segments Covered |
By Type, By Application, By Distribution Channel, By Region |
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
Key Companies |
Elicityl S.A., Abbott Laboratories, Biosynth Carbosynth, Dextra Laboratories Ltd., Dupont Nutrition & Biosciences, Glycosyn, BASF S.E., Glycom A/S, Nestle Health Science, Neolacta Lifesciences Pvt. Ltd, Royal DSM, Medolac Laboratories, Chr. Hansen Holding A/S, ZuChem, Inbiose NV, and Royal FrieslandCampina N.V. |
For Specific Research Requirements |